Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.
McKesson Corp. said the company and two other major U.S. drug distributors could be expected to pay up to $21 billion under a new proposal by state attorneys general to resolve lawsuits alleging they helped fuel the U.S. opioid crisis.
U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
Klick Health announced the addition of more accomplished Creative trailblazers to its team as the independent agency continues to experience record-breaking growth.
Less than a month after the failure of a Phase III Duchenne muscular dystrophy (DMD) trial, Switzerland-based Santhera Pharmaceuticals announced a corporate restructuring that includes the termination of 50 percent of the company’s workforce.
Paris-based Sanofi and Amsterdam-based Kiadis Pharma inked a deal for Sanofi to acquire the entire share capital of Kiadis.
Novo Nordisk ended development of the anti-IL-21 antibody NN9828 in combination with Victoza after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
Shares of Bellicum Pharmaceuticals plunged following an announcement that the company will slash 79% of employees as part of a restructuring following the developmental pause for one CAR-T program.
Syneos Health announced an agreement to acquire Synteract, a full-service contract research organization (CRO) focused on the biopharmaceutical industry.
